A Historic Turning Point: ODAC Unanimously Votes in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments
IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.”